Momentum Biotechnologies News and Resources

Momentum Biotechnologies has successfully acquired OmicScouts GmbH, a contract research organisation (CRO) based in Munich, Germany. The move strengthens Momentum’s position in mass spectrometry-based drug discovery and enables geographic expansion into the European market. OmicScouts will continue operations under its new name, OmicScouts,

Momentum Biotechnologies, a Contract Research Organization (CRO) specialising in mass spectrometry-based drug discovery, has formed a strategic partnership with Cube Biotech, a company known for its expertise in membrane protein targets. The partnership will integrate Cube Biotech’s advanced protein technology